Přístupnostní navigace
E-přihláška
Vyhledávání Vyhledat Zavřít
Detail publikace
FOJTŮ, M. GUMULEC, J. STRAČINA, T. RAUDENSKÁ, M. SKOTÁKOVÁ, A. VACULOVIČOVÁ, M. ADAM, V. BABULA, P. NOVÁKOVÁ, M. MASAŘÍK, M.
Originální název
Reduction of doxorubicin-induced cardiotoxicity using nanocarriers: A review
Typ
článek v časopise ve Web of Science, Jimp
Jazyk
angličtina
Originální abstrakt
Background: Anthracycline antibiotic doxorubicin (DOX) is a very potent and extensively prescribed chemotherapeutic drug. It is widely utilized in the therapy of variety of haematological and solid tumours, although its administration is commonly accompanied with several severe side effects. The most serious one is a development of dose-dependent and cumulative cardiotoxicity. In the course of time, many strategies have been investigated in order to avoid or at least to diminish DOX-induced cardiac dysfunction; these include reduction of toxic effect by co-administration with iron chelators (dexrazoxane), trastuzumab, taxanes, statins, and ACE-inhibitors. However, the attenuation of cardiotoxic effect is still not satisfactory yet.
Klíčová slova
Doxorubicin; nanoparticles; liposomal; polymeric; protein; gold; cardiotoxicity; nanocarriers
Autoři
FOJTŮ, M.; GUMULEC, J.; STRAČINA, T.; RAUDENSKÁ, M.; SKOTÁKOVÁ, A.; VACULOVIČOVÁ, M.; ADAM, V.; BABULA, P.; NOVÁKOVÁ, M.; MASAŘÍK, M.
Vydáno
11. 7. 2017
ISSN
1389-2002
Periodikum
CURRENT DRUG METABOLISM
Ročník
18
Číslo
3
Stát
Stát Spojené arabské emiráty
Strany od
237
Strany do
263
Strany počet
27
BibTex
@article{BUT137709, author="Michaela {Fojtů} and Jaromír {Gumulec} and Tibor {Stračina} and Martina {Raudenská} and Anna {Skotáková} and Markéta {Vaculovičová} and Vojtěch {Adam} and Petr {Babula} and Marie {Nováková} and Michal {Masařík}", title="Reduction of doxorubicin-induced cardiotoxicity using nanocarriers: A review", journal="CURRENT DRUG METABOLISM", year="2017", volume="18", number="3", pages="237--263", doi="10.2174/1389200218666170105165444", issn="1389-2002" }